Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral

JAMA

Volumn 288, Issue 14, 2002, Pages 1749-1757

  Kulasingam, Shalini L ^b,d   Hughes, James P ^b   Kiviat, Nancy B ^b   Mao, Constance ^c   Weiss, Noel S ^b   Kuypers, Jane M ^b   Koutsky, Laura A ^a,b  

^a HPV Research Group   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; VIRUS DNA;

ACCURACY; ADULT; ARTICLE; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; DNA DETERMINATION; DNA RNA HYBRIDIZATION; EPITHELIUM; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LIQUID; MAJOR CLINICAL STUDY; METHODOLOGY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REPRODUCTION; SCREENING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; STANDARD; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX DISEASE; UTERINE CERVIX TUMOR; WART VIRUS;

EID: 0037048697     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.14.1749     Document Type: Article

References (29)

1. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989;261: 737-743.
2. Gay JD, Donaldson LD, Goellner JR. False negative results in cervical cytologic studies. Acta Cytol. 1985;29:1043-1046.
3. National Cancer Institute. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA. 1989;262:931-934.
4. Sasieni PD, Cuzick J, Lynch-Framery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. BrJ Cancer. 1996;73:1001-1005.
5. Confortini M, Biggeri A, Cariaggi MP, et al. Intralaboratory reproducibility in cervical cytology: results of the application of a 100-slide set. Acta Cytol. 1993; 37:49-54.
6. Klinkhamer PJ, Vooijs GP, de Haan AF. Intra-observer and interobserver variability in the diagnosis of epithelial abnormalities in cervical smears. Acta Cytol. 1988;32:794-800.
7. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
8. Solomon D, Schiffman M, Tarone B, for the ALTS Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
9. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon, France: World Health Organization; 1995. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 64.
10. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87: 796-802.
11. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
12. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87: 1365-1371.
13. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-1638.
14. Cuzick H, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer. 1999; 81:554-558.
15. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet. 1995;345:1533-1536.
16. Ratnam S, Franco E, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:945-951.
17. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a meta-analysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001;185: 308-317.
18. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
19. Luff RD. The Bethesda system for reporting cervical/ vaginal cytologic diagnoses: report of the 1991 Bethesda Workshop. Hum Pathol. 1992;23:719-721.
20. Center for Devices and Radiological Health, US Food and Drug Administration. Clinical Laboratory Improvement Methods. 2002. Available at: http:// www.fda.gov/cdrh/clia. Accessibility verified September 13, 2002.
21. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types using L1 consensus PCR products by a single hybridization reverse line-blot detection method. J Clin Microbiol. 1998;36:3020-3027.
22. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993: 436.
23. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high risk HPV types by the signal amplification 2 test. J Med Virol. 2001;65:155-162.
24. Peyton CL, Schiffman M, Lörlncz AT, et al. Comparison of PCR- and signal amplification-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998;36:3248-3254.
25. ALTS Group. Human papillomavirus testing as a triage strategy for women with cytologic evidence of low grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000; 92:397-402.
26. Eger RR, Peipert JF. Risk factors for noncompliance in a colposcopy clinic. J Reprod Med. 1996; 41:671-674.
27. Paskett ED, Phillips KC, Miller ME. Improving compliance among women with abnormal Papanicolaou smears. Obstet Gynecol. 1995;86:353-359.
28. Schneider A, Hoyer H, Lotz B, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529-534.
29. Khanna N, Phillips MD. Adherence to care plan in women with abnormal Papanicolaou smears: a review of barriers and interventions. J Am Board Fam Pract. 2001;14:123-130.